This study is recruiting. It focuses on bipolarity and currently lists participation information in Argentina, Australia, Bulgaria, Hungary, Japan, New Zealand, Poland, and the United States.
This study is looking at evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder for people with Bipolar-I Disorder With Mania or Mania With Mixed Features. Participants are followed over time so researchers can learn from clinical and follow-up information. This study may not offer a new treatment, and its main value is helping researchers learn from follow-up information that may improve future care.
The official record suggests in-person participation through a hospital, with sites including Pillar Clinical Research - Bentonville, Woodland International Research Group in Little Rock, and Advanced Research Center Inc in Anaheim. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually matching the main diagnosis. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
This page links back to the public source record so people can verify details directly with the registry and research team.
If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.
Open source recordThis form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Argentina.
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
This study is exploring observational follow-up for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.
This study is sponsored by Bristol-Myers Squibb, a pharmaceutical company. The company develops medicines across several therapeutic areas, including oncology, hematology, immunology, cardiovascular disease, and neuroscience. The sponsor is based in the United States. Sponsor website: https://www.bms.com. You can verify the sponsor and study responsibility in the official registry record.
This study may involve observational follow-up, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.
Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.